Predict your next investment

HEALTHCARE | Drug Development
poxelpharma.com

See what CB Insights has to offer

Founded Year

2009

Stage

IPO | IPO

Total Raised

$51.12M

Date of IPO

2/6/2015

Market Cap

0.14B

About Poxel

Poxel is a biopharmaceutical company developing first-in-class drugs, with a primary focus on Type 2 diabetes. The company develops drug candidates to clinical proof-of-concept before seeking pharmaceutical industry partners. Poxel was spun out from Merck Serono. It operates independently as a lean organization with strong in-house drug development expertise.Poxel's product pipeline consists of several first-in-class Type 2 diabetes products, including Imeglimin in Phase II development. Recently, Imeglimin has also shown significant clinical benefits in Type 2 diabetes, when added to sitagliptin. The Phase II study achieved the primary and secondary endpoints. Previously, Imeglimin has shown incremental efficacy as an add-on therapy to metformin, in patients inadequately controlled by monotherapy. In addition, a direct activator of AMPK is in preclinical development for the treatment of Type 2 diabetes.

Poxel Headquarter Location

200 avenue Jean Jaurès

Lyon, 69007,

France

+33 437 372 012

Latest Poxel News

Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in November

Nov 3, 2021

November 03, 2021 02:30 AM Eastern Daylight Time LYON, France--( BUSINESS WIRE )-- POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in November 2021. AASLD The Liver Meeting (virtual) Date: November 12-15, 2021 Poxel will present a poster entitled: “FIB-4 score as a predictive factor of advanced liver fibrosis should be adapted according to type 2 diabetes status: screening data from DESTINY-1 (PXL065) phase 2 study.” Jefferies London Healthcare Conference (in-person and virtual) Date: November 16-19, 2021 London, UK Poxel management team members will be available for one-to-one in-person meetings on November 16-17, 2021, and for virtual meetings on November 18, 2021. Thomas Kuhn, CEO, will present on November 16, 2021 at 1:00pm GMT / 8:00 am ET. 5th Annual NASH Summit (virtual) Date: November 29 - December 2, 2021 David Moller, Executive Vice President, Chief Scientific Officer (CSO), will participate and present at this conference. As part of increasing its focus on rare diseases and on X-linked adrenoleukodystrophy (ALD), a severe orphan neurometabolic disease with no approved therapies, Poxel will also be represented at the following events: ALD Connect Annual Meeting (virtual) Date: November 12-13, 2021 David Moller, Executive Vice President, Chief Scientific Officer (CSO), will participate and present at this conference Poxel programs targeting adrenoleukodystrophy (ALD). Alex The Leukodystrophy Charity Digital Community Weekend 2021 (virtual) Date: November 20-21, 2021 About Poxel SA Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY-1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG® (Imeglimin), Poxel’s first-in-class lead product that targets mitochondrial dysfunction, has been approved and launched for the treatment of type 2 diabetes in Japan. Poxel expects to receive sales-based payments and royalties from Sumitomo Dainippon Pharma. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Poxel

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Poxel is included in 2 Expert Collections, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,750 items

Poxel Patents

Poxel has filed 18 patents.

The 3 most popular patent topics include:

  • Autosomal recessive disorders
  • Rare diseases
  • Neurological disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/6/2018

10/12/2021

Transcription factors, Autosomal recessive disorders, Rare diseases, Neurological disorders, V8SuperTourer drivers

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/6/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/12/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Autosomal recessive disorders, Rare diseases, Neurological disorders, V8SuperTourer drivers

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Poxel Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Poxel Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.